HomeCompareOPHLF vs ABBV

OPHLF vs ABBV: Dividend Comparison 2026

OPHLF yields 3.22% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPHLF wins by $9.70M in total portfolio value· pulled ahead in Year 3
10 years
OPHLF
OPHLF
● Live price
3.22%
Share price
$14.55
Annual div
$0.47
5Y div CAGR
76.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.80M
Annual income
$8,123,319.23
Full OPHLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OPHLF vs ABBV

📍 OPHLF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPHLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPHLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPHLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPHLF
Annual income on $10K today (after 15% tax)
$273.36/yr
After 10yr DRIP, annual income (after tax)
$6,904,821.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OPHLF beats the other by $6,883,765.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPHLF + ABBV for your $10,000?

OPHLF: 50%ABBV: 50%
100% ABBV50/50100% OPHLF
Portfolio after 10yr
$4.95M
Annual income
$4,074,045.49/yr
Blended yield
82.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OPHLF
No analyst data
Altman Z
4.8
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPHLF buys
0
ABBV buys
0
No recent congressional trades found for OPHLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPHLFABBV
Forward yield3.22%3.06%
Annual dividend / share$0.47$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR76.7%40.6%
Portfolio after 10y$9.80M$102.3K
Annual income after 10y$8,123,319.23$24,771.77
Total dividends collected$9.63M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OPHLF vs ABBV ($10,000, DRIP)

YearOPHLF PortfolioOPHLF Income/yrABBV PortfolioABBV Income/yrGap
1$11,268$568.26$11,550$430.00$282.00ABBV
2$13,114$1,057.44$13,472$627.96$358.00ABBV
3← crossover$16,065$2,032.36$15,906$926.08+$159.00OPHLF
4$21,301$4,111.31$19,071$1,382.55+$2.2KOPHLF
5$31,794$9,002.23$23,302$2,095.81+$8.5KOPHLF
6$56,209$22,189.83$29,150$3,237.93+$27.1KOPHLF
7$124,928$64,784.43$37,536$5,121.41+$87.4KOPHLF
8$371,454$237,780.36$50,079$8,338.38+$321.4KOPHLF
9$1,564,997$1,167,541.06$69,753$14,065.80+$1.50MOPHLF
10$9,797,866$8,123,319.23$102,337$24,771.77+$9.70MOPHLF

OPHLF vs ABBV: Complete Analysis 2026

OPHLFStock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Full OPHLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OPHLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPHLF vs SCHDOPHLF vs JEPIOPHLF vs OOPHLF vs KOOPHLF vs MAINOPHLF vs JNJOPHLF vs MRKOPHLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.